Home > Healthcare > Pharmaceuticals > Drug Delivery > Inhalable Drugs Market

Inhalable Drugs Market Trends

  • Report ID: GMI10744
  • Published Date: Aug 2024
  • Report Format: PDF

Inhalable Drugs Market Trends

Advancements in inhalation technology have transformed the delivery and efficacy of inhalable drugs, leading to substantial improvements in patient outcomes and treatment adherence. Innovations in particle engineering and formulation techniques, alongside the evolution of smart inhalers, which is estimated to reach USD 3.3 billion by 2032, and personalized medicine approaches, have played pivotal roles. These advancements have not only enhanced drug delivery efficiency but also empowered patients with increased convenience and greater control over their healthcare decisions.
 

  • Innovations in particle engineering, including techniques like spray drying and supercritical fluid technology, have facilitated the creation of highly respirable dry powders. These powders are designed to enhance deposition in the lungs while minimizing deposition in the throat, thereby improving the efficiency of drug delivery.
     
  • Smart inhalers are equipped with advanced sensors and connectivity features that revolutionize the management of respiratory conditions. These devices not only monitor usage patterns but also provide real-time feedback to patients, promoting adherence to prescribed treatment regimens. By connecting to mobile apps, smart inhalers facilitate seamless data sharing with healthcare providers, enabling remote monitoring and timely interventions.
     
  • Additionally, inhalers are increasingly being designed to deliver multiple drugs simultaneously, such as bronchodilators and corticosteroids. This combination approach simplifies treatment regimens and improves patient compliance, thus propelling the growth of the market.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global inhalable drugs industry was valued at USD 33.4 billion in 2023 and is anticipated to register 6.8% CAGR between 2024 and 2032 due to the increasing prevalence of respiratory diseases and advancements in inhalation technology.

The respiratory diseases segment in the market recorded USD 24.2 billion in 2023 due to targeted lung delivery, rapid onset, and improving efficacy.

U.S. inhalable drugs market is projected to reach USD 21.8 billion by 2032 due to increasing pharmaceutical and biotechnological innovation and rising investment in R&D.

AstraZeneca Plc, C.H. Boehringer Sohn AG & Co. KG., CHIESI Farmaceutici S.p.A., Cipla Limited, GSK plc, MannKind Corporation, Merck & Co., Inc., Mundipharma International., Novartis AG, and Pfizer Inc., among others.

Inhalable Drugs Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 16
  • Tables & Figures: 210
  • Countries covered: 23
  • Pages: 117
 Download Free Sample